namah sivaya
4 년 전
LKYSF news of trial with MAPS!
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation
Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD
VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.
"We are excited to share an update on the progress of our MDMA compassionate access trial with the full recognition that existing therapies for PTSD are inadequate," said Payton Nyquvest, CEO of Numinus. "At Numinus, we are pleased to help foster a promising regulatory landscape that will contribute to a better understanding that psychedelic-assisted psychotherapies are a viable, safe, and necessary avenue for expanding existing treatment options. We look forward to continued collaboration with the Multidisciplinary Association of Psychedelics for Studies (MAPS PBC) and will work together to provide those experiencing PTSD with more treatment options."
This first-of-its-kind trial in Canada has advanced and successfully transitioned into the pre-implementation stage at Numinus' Vancouver clinic. This follows the successful completion of several milestones, starting with the recruitment of therapists, physicians, and staff in preparation for participant enrolment and the ultimate analysis of therapy outcomes. The highly qualified cohort of medical staff will be responsible for collecting safety data for Health Canada to further implement key research that supports individuals living with PTSD who have not benefited from existing treatment options.
In November 2020, eight Numinus therapists graduated from Part B of the MAPS MDMA therapist training program. Through their roles within the trial, they will complete the supervision requirement for certification as fully qualified MDMA therapists.
A draft MDMA-assisted therapy protocol for PTSD has been adapted for the trial, including clear guidance surrounding necessary screening processes, patient health histories, and indications and potential contraindications before accepting participants. Initial regulatory meetings with Health Canada to define the trial's implementation science strategy have been completed, and the next steps will include obtaining ethical and Health Canada approvals to allow the recruitment of participants according to COVID-19 public health protocols.
"Developing a skilled workforce is a key challenge for the safe delivery of psychedelic-assisted therapies, so we are pleased to engage with Numinus to train therapists in the MDMA-assisted therapy protocol for PTSD," said Amy Emerson, CEO of MAPS PBC.
Numinus is also pleased to announce that its Medical and Therapeutic Services Director, Dr. Devon Christie, will serve as both the trial's Principal Investigator and as a therapist. Dr. Christie is a family physician with a focus in multidisciplinary pain management, is a certified Relational Somatic Therapist, and is already MAPS-trained in the delivery of the MAPS MDMA-assisted therapy for PTSD.
"I am thrilled to be involved in a long-awaited clinical program that will help pave the way towards wider use of MDMA-assisted psychotherapy for those experiencing PTSD," said Dr. Christie. "The key milestones announced today are a true testament to our teams' commitment to establishing the physical, technical, clinical, and human resource infrastructure needed to swiftly move through the trial's formal implementation stages and ultimately towards the recruitment of the first participant."
https://www.newswire.ca/news-releases/numinus-announces-milestones-in-compassionate-access-trial-for-mdma-assisted-therapy-in-collaboration-with-maps-public-benefit-corporation-819950387.html
namah sivaya
4 년 전
New article quoting CEO of LKYSF....
Psychedelics Sentiment Strong, Investors Ready for New Year
After a welcome party of a year for the psychedelics investing space, how exactly does investor appetite stand as the new year begins?
The psychedelics investment proposal has started to grab the attention of investors across the board as more companies begin hitting the public markets.
While it’s clear attention is rising, the Investing News Network (INN) spoke with two companies to get their thoughts on investor interest and how they see this new market.
“It seems incredibly strong,” Ronan Levy, co-founder and executive director with Field Trip Health (CSE:FTRP), said of current investor sentiment towards psychedelics.
Levy said his company recently completed a bought deal raising, which was oversubscribed by about two and a half times from the original deal. “The demand seems to be pretty palpable, both on an institutional level as well as on a retail level,” he told INN.
The new year has brought an uptick in offerings from psychedelics companies. In January, companies such as Mind Cure Health (CSE:MCUR,OTCQB:MCURF), Havn Life Sciences (CSE:HAVN), Cybin (NEO:CYBN) and Mind Medicine (MindMed) (NEO:MMED,OTCQB:MMEDF) all confirmed significant investment deals.
Payton Nyquvest, chairman and CEO of Numinus Wellness (TSXV:NUMI), told INN the psychedelics industry has experienced a perfect storm of validation from the financial community as well as the regulatory space thanks to increased acceptance from investors, along with recent policy updates that have further opened the doors to psychedelics.
Nyquvest said he spends the majority of his time with potential investors clarifying key questions about the space, such as the actual logistics of psychedelics-assisted psychotherapy, regulatory timelines for policy changes and the legal framework in place.
When it comes to the type of investors associated with the space at the moment, Levy said there certainly are some looking for an exciting trade opportunity given the bump in attention for this market.
However, many are appreciating the long-term nature of the psychedelics industry.
“Most of the investors I can say that we brought in as part of our our bought deal understood the long-term potential and that this is an evolving industry and it’s going to have its ups and downs,” Levy said.
psychedelics outlook
How to differentiate psychedelics investments?
With increased demand from the market, the psychedelics space has seen a rush of brand new listings and emerging companies fighting for the attention of a growing investor base.
Nyquvest told INN he recommends that investors pay attention to the people involved with these companies first and foremost. “My question is always, ‘What is their research and implementation plan?’ And then looking at what it costs,” the Numinus executive said.
He stressed that investors need to be ready to comprehend the demands of research work and the amount of time this represents for companies.
Nyquvest said he’s encouraged by the discussions on due diligence that he’s seeing surrounding the space as more companies go public.
First psychedelics fund shows growing investor demand
At the end of January, Horizons ETFs Management (Canada) launched the first exclusively dedicated psychedelics exchange-traded fund (ETF) in the industry. The Horizons Psychedelic Stock Index ETF (NEO:PSYK) came to the market with a basket of 17 stocks.
Steve Hawkins, CEO of Horizons ETFs, told INN his company started doing research on psychedelics early in 2020, when attention was first starting to fall on the sector.
The firm was previously responsible for launching the first Canadian cannabis ETF, and the executive said for that reason Horizons ETFs quickly started getting questions and seeing general interest from investors about a potential psychedelics ETF.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
https://investingnews.com/daily/life-science-investing/psychedelics-investing/psychedelics-sentiment-strong-new-year/
namah sivaya
4 년 전
Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing
Acquisition expands Numinus' presence while improving psychedelic-assisted therapy landscape in Canada
VANCOUVER, BC, Feb. 8, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), has closed its acquisition of Mindspace Psychology Services Inc. (DBA Mindspace Wellbeing), a leader and pioneer in psychedelic programming. The purchase agreement was previously announced on December 15, 2020.
Founded by Dr. Joe Flanders in 2011, Mindspace will continue under Dr. Flanders' leadership. The acquisition expands Numinus' presence into Quebec, building on its Vancouver office with two established locations and extensive virtual services as well as insights garnered from a decade of successful clinic management.
Terms of the agreement:
Numinus paid the following consideration to complete the Transaction:
$500,000 in cash upon closing of the Transaction
A time-based payout of 441,176 common shares of Numinus issued over the course of 24 months
$100,000 in Numinus shares, issued at Market Price, per year on each of the first three (3) anniversaries of the Closing Date
A multi-year performance payout of $800,000 in Numinus shares, issued at Market Price
https://www.newswire.ca/news-releases/numinus-wellness-completes-acquisition-of-montreal-based-mindspace-wellbeing-891369191.html
namah sivaya
4 년 전
This should be good for the trading of LKYSF common to have warrants listed and freely trading....
VANCOUVER, BC, Jan. 21, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing the 12,683,925 warrants (the "Warrants") issued pursuant to the Company's previously announced prospectus offering that closed on December 29, 2020.
The Warrants will be listed for trading on the TSXV under the symbol "NUMI.WS" effective at market open on Monday, January 25, 2021.
Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.90 until December 29, 2022. The Warrants were issued pursuant to, and are governed by, the terms of a warrant indenture dated December 29, 2020 (the "Warrant Indenture") between the Company and Computershare Trust Company of Canada. A copy of the Warrant Indenture is available under the Company's SEDAR profile at www.sedar.com.
https://www.newswire.ca/news-releases/numinus-announces-listing-of-warrants-893519003.html
Hot Features
프리미엄
실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
ListenToMe
3 월 전
MomsSpaghetti
12 월 전
Stepbro69
12 월 전
TommyBoyTrader9460
12 월 전
rtrstock
3 년 전
Renee
3 년 전
Pennybuster
3 년 전
WallStreetMyWay
4 년 전
Dewayne18
4 년 전
slambino
4 년 전
ED25
4 년 전
VwapWickHunter125x
4 년 전
nowwhat2
4 년 전
hotmeat
4 년 전
